Search Within

Aisara Chansakul

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (7)
  2. Bone Marrow Transplant (7)
  3. Center for Hematologic Malignancies (7)
  4. Department of Medicine (7)
  5. Epidemiology and Biostatistics (7)
  6. Hematologic Malignancies Research (7)

More Groups

People
  1. Alexander Lesokhin (7)
  2. Carl Landgren (7)
  3. Meghan Salcedo (7)
  4. Elizabet Tavitian (6)
  5. Ahmet Dogan (5)
  6. Allison Sams (5)

More People

Years
  1. 2021 (1)
  2. 2020 (2)
  3. 2019 (3)
  4. 2018 (1)
Publications
  1. Blood (5)
  2. Blood Advances (1)
  3. JAMA Oncology (1)
Publishers
  1. American Society of Hematology (6)
  2. American Medical Association (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
    Journal Article

    Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L.; Tavitian, E.; Slingerland, J. B.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Intestinal microbiota composition is associated with minimal residual disease negativity in patients with multiple myeloma
    Meeting Abstract

    Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L. L.; Tavitian, E.; Slingerland, J. B.; more...
    Blood (2018)

    Fulltext@MSK | Save